Skip to main content

and
  1. No Access

    Article

    Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy

    The discovery of effective therapeutic treatments for cancer via cell differentiation instead of antiproliferation remains a great challenge. Cyclin-dependent kinase 2 (CDK2) inactivation, which overcomes the ...

    Liguo Wang, Xue**g Shao, Tianbai Zhong, Yue Wu, Aixiao Xu in Nature Chemical Biology (2021)